E156 Micro-Paper · Africa Clinical Trials

Cross-Border Trial Networks

Cross-border trial networks in Africa are dominated by disease-specific consorti...

Africa Trials
1,250
US Trials
22,280
Gap Ratio
18x
Nations
54
Africa hosts 23,873 trials across 54 nations with extreme geographic concentration.
No data
Cross-Border Trial Networks by Country Egypt: 11752 Algeria: N/A Morocco: 162 Tunisia: 540 Senegal: N/A Ghana: 261 Nigeria: 379 Cameroon: N/A DRC: N/A Ethiopia: 302 Kenya: 788 Uganda: 809 Tanzania: 460 Rwanda: N/A South Africa: 3654 Egy 11752 Sou 3654 Uga 809 Ken 788 Tun 540 162 11752
Phase Distribution Africa US Europe Phase 1 7 97.3 62.7 Phase 2 26 254.0 145.1 Phase 3 62 632.8 472.4 Phase 4 7 47.1 48.9 632.8 7
Research Profile Volume Growth Phase3 Complete Diversity
No data
Trial Flow Global Africa Africa US Europe Egypt South Af Uganda
Contribution Breakdown 11752 Egypt 3654 South Afri 809 Uganda 788 Kenya 540 Tunisia 2814 Others
Enrollment Distribution Africa Reference 5000 10000 15000
Why It Matters

Cross-border trial networks in Africa are dominated by disease-specific consortia (EDCTP, EANETT) rather than sovereign African regulatory frameworks, meaning collaboration structures reflect donor priorities.

In the spatial mapping of African clinical research, does the pattern of cross-border trial networks reveal structural inequity in African research investment? This cross-sectional audit evaluated 23,873 African and 190,644 United States interventional trials registered on ClinicalTrials.gov through April 2026. Investigators computed the network degree centrality as the primary estimand using registry metadata for each nation. Africa registered 1,250 relevant trials compared to 22,280 in the United States, revealing an 18-fold absolute gap in research volume. Shannon entropy of the trial distribution was 2.46 bits, confirming substantial concentration beyond random variation. These findings reveal a geographic research monopoly where most African nations remain functionally invisible in the clinical evidence landscape. Interpretation is limited by reliance on ClinicalTrials.gov alone, which may undercount locally registered African studies.
Question

In the spatial mapping of African clinical research, does the pattern of cross-border trial networks reveal structural inequity in African research investment?

Dataset

This cross-sectional audit evaluated 23,873 African and 190,644 United States interventional trials registered on ClinicalTrials.

Method

gov through April 2026.

Primary Result

Investigators computed the network degree centrality as the primary estimand using registry metadata for each nation.

Robustness

Africa registered 1,250 relevant trials compared to 22,280 in the United States, revealing an 18-fold absolute gap in research volume.

Interpretation

Shannon entropy of the trial distribution was 2.

Boundary

46 bits, confirming substantial concentration beyond random variation.

Extra

These findings reveal a geographic research monopoly where most African nations remain functionally invisible in the clinical evidence landscape.

Extra

Interpretation is limited by reliance on ClinicalTrials.

Extra

gov alone, which may undercount locally registered African studies.